Sanfilippo syndrome type B or mucopolysaccharidosis type IIIB (MPS IIIB) is one of a group of lysosomal storage disorders that are characterised by the inability to breakdown heparan sulphate. In MPS IIIB, there is a deficiency in the enzyme a-N-acetylglucosaminidase (NAGLU) and early clinical symptoms include aggressive behaviour and hyperactivity followed by progressive mental retardation. The disease is autosomal recessive and the gene for NAGLU, which is situated on chromosome 17q21, is approximately 8.5 kb in length and contains six exons. Primers were designed to amplify the entire coding region and intron/exon boundaries of the NAGLU gene in 10 fragments. The PCR products were analysed for sequence changes using SSCP analysis and fluorescent DNA sequencing technology. Sixteen different putative mutations were detected in DNA from 14 MPS IIIB patients, 12 of which have not been found previously. The mutations include four deletions (219-237de119, 334-358del25, 1335delC, 2099delA), two insertions (1447( -1448insT, 1932, two nonsense mutations (R297X, R626X), and eight missense mutations (F48C, Y140C, R234C, W268R, P521L, R565W, L591P, E705K). In this study, the Y140C, R297X, and R626X mutations were all found in more than one patient and together accounted for 25% of mutant alleles. (7Med Genet 1998;35:910-914) 
Sanfilippo syndrome type B or mucopolysaccharidosis type IIIB (MPS IIIB) is a lysosomal storage disorder that is caused by the deficiency of the enzyme a-N-acetylglucosaminidase (NAGLU). NAGLU catalyses the removal of the N-acetylglucosamine residues from the non-reducing terminal of heparan sulphate during lysosomal degradation. The deficiency results in the accumulation inside lysosomes and excretion in the urine of heparan sulphate. Diagnosis is based on detection of excessive urinary heparan sulphate and by demonstration of a deficiency of NAGLU in white blood cells, plasma, or fibroblasts.' Clinical symptoms are initially characterised by intractable hyperactivity and aggressive behaviour, followed by progressive mental retardation with death usually in the late teens. A more slowly progressive form of the disease with later onset, known as the attenuated phenotype, has been described in a small number of MPS IIIB patients.2" MPS IIIB is autosomal recessive and the gene encoding the a-N-acetylglucosaminidase enzyme (NAGLU) has been characterised recently."6 The gene which is situated on chromosome 17q21, is approximately 8.5 kb in length and contains six exons. The cDNA is 8.2 kb long and encodes a protein of 743 amino acids. Characterisation of the genomic structure of the NAGLU gene (Genbank accession number U43572) has made it possible to start mutational analysis. There is evidence of clinical variability among MPS IIIB patients and this variation may be the result, in part, of the involvement of different allelic mutations.' At present, 23 Table 4 details the genotype of the patients including their national origin. Eight of the patients were homozygous for their mutations and the remaining six were compound heterozygotes. Three of the mutations, Y140C, R297X, and R626X, were found in more than one patient.
The pathogenic nature of the six novel missense mutations on enzyme function has yet to be ascertained, but 94 control chromosomes were screened to determine if the changes were present in the general population. SSCP analysis was used to screen for four of the changes (F48C, W268R, R565W, E705K). Digestion with the restriction enzyme HhaI was used to detect R234C. ACRS PCR and BstUI digestion was used to screen for L59 1 P. None of the changes was found in any of the 94 control chromosomes. Two polymorphisms in which the amino acid sequence was not altered were found in the control chromosomes. They were R519R (AGG-AGA: 1557G>A) and P719P (CCG->CCA: 2157G>A). Each occurred in heterozygous form in a single control and both appear to be very rare (1.1%).
Discussion
Mutational analysis on 14 patients with the severe classical form of MPS IIIB has resulted in the identification of 16 putative mutations, 12 of which have not been previously described. Two putative mutations have been found in all 14 patients. Eight patients were homozygous for the sequence changes and the remaining six were compound heterozygotes.
Among the 12 novel sequence changes there were four deletions and two insertions. In the larger insertions and deletions, analysis of the sequence adjacent to or within the affected region shows the presence of direct repeat elements which have probably played a role in the mutation event.'4 '5 In the 219-237del19 mutation, where there has been a deletion of 19 bp, there is a 7 bp direct repeat element (GCGCGGC) just before the deletion site and at the 3' end of the deleted fragment. The 334-358de125 mutation, a deletion of 25 bp, shows a similar pattern with a 5 bp direct repeat element TGCCG; however, there has been a deletion of an additional four G residues from the sequence just after the second direct repeat. There is a 3 bp direct repeat element GCT present in the vicinity of the 1932-1933insGCTAC mutation where five bases have been inserted between nucleotides 1932 and 1933. Two of the single base pair deletions, 2099delA and 1335delC, have occurred after a sequence of four A residues or four C residues, respectively. The 1447-1448insT mutation has occurred after a single T residue. All three have clearly arisen as a result of slipped mispairing during DNA replication.'4 '5 These insertions and deletions will be pathogenic since all of them cause a shift in the reading frame and five of the six will result in premature termination. The exception is 2099delA which occurs close to the C-terminus of the protein. The last 44 amino acids of the normal protein will be altered and an additional 22 amino acids added to the C-terminus (the new stop codon will be situated in the polyadenylation signal AT-TAAA). Since the C-terminus is a critical part of the protein, any alteration will affect its secondary structure and ultimately its function.
Two nonsense mutations were found in the group of patients studied, R297X and R626X, both of which have been previously reported.69 Only these two mutations and the pathogenic Y140C mutation8 were found in more than one MPS IIIB patient. Together they account for 25% of mutant alleles and are therefore relatively common. They occur in several different populations (table 4) and since the two premature stop mutations occur at CpG dinucleotides they have probably occurred independently in different parts of the world. In contrast, the Y140C mutation, which does not occur at a CpG dinucleotide, may be an ancient mutation. In the seven UK patients, the three "common" mutations account for 36% of mutant alleles and such information will be important for future screening of newly diagnosed MPS IIIB patients in the UK.
CpG dinucleotides in a gene sequence are known to be "mutational hotspots".16 Of the 10 point mutations, five occur at a CpG dinucleotide. Eight of the point mutations were missense and none of the six novel missense mutations was found in 94 control chromosomes. In the patients who were homozygous for a particular missense mutation, no other sequence changes were found. This provides preliminary evidence for the pathogenic nature of these changes. Three of the mutations (W268R, R565W, E705K) alter the charge of the amino acid side chain, which is likely to affect the conformation, stability, or catalytic function of the NAGLU enzyme. Two of the mutations (F48C, R234C) result in the introduction of an extra cysteine residue into the protein chain and this may alter disulphide bridge formation. There is no alteration in the charge of the side chain in the L59 1 P mutation, but the acquisition of a proline residue is likely to affect secondary structure formation.
A previous study found that nine out of 10 missense mutations were clustered in one of two regions of the protein, between codons 92 and 153, and codons 612 and 682.8 It was suggested that these regions may be important in the transport or function of the enzyme.8 However, none of the six novel missense mutations found in this study lie in either of these two regions. Since very little is known about the catalytic site of the enzyme, it is very difficult to draw any conclusions as to the effect of the missense mutations on enzyme function. Six potential N-glycosylation sites with the NXS/T motif have been proposed.6 None of the mutations presented in this report disrupt any of these potential N-glycosylation sites. The mouse NAGLU enzyme has been characterised recently (Genbank accession number MMU85247)8 and shows 84% homology at the amino acid level to the human form. The six novel missense mutations in this report result in the substitution of residues that are conserved in the mouse and human NAGLU enzymes. Future analysis of the precise effect of these missense mutations on enzyme transport and function will lead to a greater understanding of the structural and functional characteristics of the enzyme.
Including the results from this study, the total number of mutations identified so far in the NAGLU gene of MPS IIIB patients is now 35. Only seven of these mutations (P115S, Y140C, R297X, Y455C, R626X, R674C, R674H)6 8 9 have been found in more than one family, the remaining 28 are, so far, confined to individual pedigrees. These results further highlight the heterogeneity of MPS IIIB at the molecular level.
